Forest-Gedeon Richter drug misses overall goal
More info…
TEL AVIV (MarketWatch) — Forest Laboratories Inc. and Gedeon Richter PLC said Monday that in a Phase II study of cariprazine, a potential treatment for bipolar depression, the overall result for patients taking the drug was not statistically different from that of the patients taking placebo. In higher doses, however, the antipsychotic drug did show “evidence of a clinically relevant treatment …
Growing up bipolar: ‘Nobody was on my side’
More info…
Jennifer Konjoian was 10 years old when she put a plastic bag over her head. She remembers doing it impulsively, for no other reason than to get attention.